DNTTIP2 functions as a multi-domain regulatory protein with roles in transcriptional regulation and ribosome biogenesis. The protein interacts with terminal deoxynucleotidyltransferase (TdT) and estrogen receptor alpha, enhancing transcriptional activity of estrogen receptor 1. It also functions as a chr1 remodeling protein capable of binding core histones and modulating TdT activity 2. Beyond transcriptional control, DNTTIP2 participates in ribosomal small subunit (SSU) biogenesis as part of the nucleolar SSU processome, where it coordinates pre-rRNA processing and modification. In disease contexts, DNTTIP2 shows clinically significant associations despite population-level constraint: elevated expression correlates with poor prognosis in pancreatic ductal adenocarcinoma, where DNTTIP2 depletion induces G1 or G2 cell-cycle arrest depending on cell type 3. DNTTIP2 was identified as a susceptibility locus for intracerebral hemorrhage in early-onset Japanese subjects 4 and as part of HBx-related prognostic signatures in hepatocellular carcinoma, where it associates with reduced anti-tumor immune infiltration and immunotherapy resistance 5. In pediatric acute myeloid leukemia, DNTTIP2 ranks among top dysregulated hub genes 6.